Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Olmesartan, microalbuminuria, and type 2 diabetes.

Lammert A, Krämer BK, Krüger B.

N Engl J Med. 2011 Jun 9;364(23):2261; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA3. No abstract available.

PMID:
21651399
2.

Olmesartan, microalbuminuria, and type 2 diabetes.

Yudkin JS, Lehman R.

N Engl J Med. 2011 Jun 9;364(23):2260; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA1. No abstract available.

PMID:
21651401
3.

Olmesartan, microalbuminuria, and type 2 diabetes.

Fioretto P, Mauer M.

N Engl J Med. 2011 Jun 9;364(23):2260-1; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA2. No abstract available.

PMID:
21651400
4.

Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.

Ingelfinger JR.

N Engl J Med. 2011 Mar 10;364(10):970-1. doi: 10.1056/NEJMe1014147. No abstract available.

PMID:
21388316
5.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

6.

Olmesartan, microalbuminuria, and type 2 diabetes.

Farmakis D, Aessopos A.

N Engl J Med. 2011 Jun 9;364(23):2261-2; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA4. No abstract available.

PMID:
21651398
7.

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A.

J Hypertens. 2006 Feb;24(2):403-8.

PMID:
16508590
9.

Diabetes: ROADMAP: the road to renoprotection?

Roscioni SS, Heerspink HJ, de Zeeuw D.

Nat Rev Nephrol. 2011 May 24;7(8):427-8. doi: 10.1038/nrneph.2011.71. No abstract available.

PMID:
21610679
10.

Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.

Ikeda H, Hamamoto Y, Honjo S, Nabe K, Wada Y, Koshiyama H.

Diabetes Res Clin Pract. 2009 Jan;83(1):117-8. doi: 10.1016/j.diabres.2008.10.013. Epub 2008 Dec 5.

PMID:
19062123
11.

Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

Chatzikyrkou C, Menne J.

Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1087-92. doi: 10.1586/erc.12.100. Review.

PMID:
23098143
12.

Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J.

J Clin Hypertens (Greenwich). 2010 Jun;12(6):422-30. doi: 10.1111/j.1751-7176.2010.00289.x. Review.

13.

Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y, Kaifu K, Hara T, Matsumoto S, Ichimura A, Ohsaki H, Hitomi H, Kawachi H, Hayden MR, Whaley-Connell A, Sowers JR, Ito S, Kohno M, Nishiyama A.

Am J Hypertens. 2012 May;25(5):604-11. doi: 10.1038/ajh.2012.1. Epub 2012 Feb 9.

14.

Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?

Consuegra-Sánchez L, Sanchis J, Núñez J, Cascón JD, Villegas M, Picó F.

Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):378-80. doi: 10.1016/j.recesp.2011.05.024. Epub 2011 Aug 12. No abstract available.

PMID:
21840109
15.

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H.

Diabetologia. 2010 Jan;53(1):49-57. doi: 10.1007/s00125-009-1577-3. Epub 2009 Oct 30.

16.

Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.

Catalá-López F, Martín-Serrano G, Maciá MA, Montero D.

Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):678-9; author reply 679-80. doi: 10.1016/j.recesp.2012.03.006. Epub 2012 May 17. English, Spanish. No abstract available.

PMID:
22608016
17.

Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.

Ritz E, Menne J, Haller H.

Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv28-30. doi: 10.1093/ndt/gfs424. No abstract available.

PMID:
23258807
18.

"ROADMAP" controversies.

Cohen DL, Townsend RR.

J Clin Hypertens (Greenwich). 2011 Aug;13(8):628. doi: 10.1111/j.1751-7176.2011.00487.x. Epub 2011 Jun 27. No abstract available.

19.

Difficult-to-control hypertension: effects of olmesartan-based combination therapies.

de la Sierra A.

J Hypertens. 2013 Mar;31 Suppl 1:S1-2. doi: 10.1097/HJH.0b013e32835d2c7e. No abstract available.

PMID:
23389082
20.

Olmesartan, migraine, and blood pressure.

Iwasaki Y, Ikeda K.

Headache. 2006 Sep;46(8):1309. No abstract available.

PMID:
16942482

Supplemental Content

Support Center